問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Linkou Chang Gung Medical Foundation (在職)

Division of Hematology & Oncology

Division of General Internal Medicine

更新時間：2023-09-19

王宏銘Wang, Hung-Ming
  • Principal Investigator
  • Clinical Trial Experience (year) 17 years 10 個月

Recruiting Trial

40Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

王宏銘

List

75Cases

2008-09-01 - 2010-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2014-04-01 - 2016-09-30

Phase III

Phase III Study of IV Vinflunine in Combination With Methotrexate Versus Methotrexate Alone in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With Platinum-based Chemotherapy

  • Condition/Disease

    Squamous Cell Carcinoma of the Head and Neck

  • Test Drug

    Javlor

Participate Sites
7Sites

Terminated7Sites

2016-04-01 - 2018-12-04

Phase I

Phase I Study of NC-6004 in Combination with 5-FU and Cetuximab as First-line Treatment in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck

  • Condition/Disease

    Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck

  • Test Drug

    NC-6004

Participate Sites
3Sites

Terminated3Sites

楊慕華
Taipei Veterans General Hospital

Division of Hematology & Oncology

王宏銘
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2020-02-29 - 2022-11-30

Phase II

Phase IIa/IIb Clinical Trial of NC-6004 in Combination With Pembrolizumab in Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Have Failed Platinum or a Platinum-containing Regimen

  • Condition/Disease

    Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

  • Test Drug

    NC-6004

Participate Sites
4Sites

Recruiting4Sites

2020-06-01 - 2021-05-31

Phase I

A phase I study to evaluate the safety, tolerability, and antitumor activity of neoantigen-expanded autologous immune cell therapy for solid tumors

  • Condition/Disease

    Advanced Solid Tumor

  • Test Drug

    Neoantigen-expanded autologous immune cell

Participate Sites
3Sites

Recruiting3Sites

1 4 5 6 7 8
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB